Background and objective: Combined pulmonary fibrosis and emphysema (CPFE) is characterized by preserved lung volume and slower lung function decline. However, it is unclear at what extent emphysema begins to impact respiratory physiology and prognostic characteristics in idiopathic pulmonary fibrosis (IPF). We estimated the extent of emphysema that could be used to define CPFE in IPF. Methods: The extent of emphysema was observed on high-resolution computed tomography scans and measured by a texture-based automated quantification system in 209 IPF patients. We analysed the impact of differences in the extent of emphysema on the annual decline rate and prognostic significance of lung function parameters. Results: The extent of emphysema was ≥5% in 53 patients (25%), ≥10% in 23 patients (11%) and ≥15% in 12 patients (6%). Patients with emphysema to an extent of ≥5% were more frequently men and eversmokers; they had more preserved lung volume and lower forced vital capacity (FVC) decline rates than those with no or trivial emphysema. The FVC decline rate was a significant predictor of mortality in patients with no or trivial emphysema (hazard ratio (HR): 0.933, P < 0.001) and in patients with an extent of emphysema ≥5% (HR: 0.906, P < 0.001). However, diffusing capacity of the lung for carbon monoxide (DL CO ) was the most significant prognostic factor in those patients with an extent of emphysema ≥10% (HR: 0.972, P = 0.040) and ≥15% (HR: 0.942, P = 0.023). A 10% cut-off value for the extent of emphysema created the most significant difference in the annual FVC decline rate in IPF patients. Conclusion: In IPF, emphysema to an extent of ≥10% affects both the annual decline rate and the prognostic
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive parenchymal fibrosis of unknown aetiology. The disease has a poor prognosis, 1 and its course in individual patients is highly variable. 2 Several physiological parameters, including forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DL CO ) and longitudinal lung function changes have been reported as prognostic predictors. 3, 4 However, their predictive capacity may be limited by insufficient respiratory effort or by complications such as emphysema or pulmonary hypertension (PH).
Patients with IPF may also have combined pulmonary fibrosis and emphysema (CPFE), because smoking is a common risk factor for both diseases. 5 In CPFE, spirometry values and lung volumes are preserved despite extensive radiographical evidence of lung disease and marked impairment of gas exchange. [6] [7] [8] The significance of longitudinal changes in lung function appears to differ between CPFE patients and IPF-only patients. In CPFE patients, FVC and DL CO declines tend to be delayed and are therefore less useful as surrogate markers of disease progression. 9, 10 In a study by Schmidt et al., longitudinal decline in forced expiratory volume in 1 s (FEV 1 ) was a better predictor of mortality than other lung function parameters or the composite physiological index (CPI) in CPFE patients, whereas the CPI was a better predictor in IPF-only patients. 9 Therefore, it is questionable whether CPFE patients should be included in trials of IPF treatment, because it can be challenging to monitor for disease progression and therapeutic response.
In any case, the emphysema extent that distinguishes CPFE patients from IPF-only patients remains unclear. Thus, we hypothesized that the emphysema extent that impacts both the annual decline rate and prognostic significance of lung function parameters could be used to define CPFE.
METHODS

Study population
This retrospective study included 209 IPF patients (biopsy-proven: 102) diagnosed at Asan Medical Center in Seoul, South Korea, between January 2004 and December 2010. The patients met the following criteria: (i) high-resolution computed tomography (HRCT) images from diagnosis were available, (ii) pulmonary function test (PFT) examinations were conducted ≥3 times in the 1 year after diagnosis and (iii) complications such as acute deterioration or lung cancer were not detected during the 1-year follow-up. Most of the patients had been participants included in our previous study. 11 Informed consent was waived and the study was approved by the Institutional Review Board (2014-0911).
Methods
Clinical and survival data for all patients were obtained from their medical records, telephonic interviews and/or the records of the National Health Insurance of Korea. Spirometry, total lung capacity (TLC) by plethysmography and DL CO were measured according to the recommendations of the American Thoracic Society (ATS) and European Respiratory Society, 12, 13 and the results were expressed as percentages of the normal predicted values. Based on FVC at 12 months, which was calculated by using linear regression, FVC change (%) was calculated as a relative change using percentage predicted FVC as follows: (FVC 12months − FVC baseline )/(FVC baseline ) × 100. The 6-min walk test (6MWT) was performed according to ATS recommendations with a slight modification 14 ; a technician followed up the patients while continuously monitoring oxygen saturation, but offered no additional remarks or encouragement to the patients. To evaluate disease extent in IPF, the CPI was calculated as follows: 91 − (0.65 × % predicted DL CO ) − (0.53 × % predicted FVC) + (0.34 × % predicted FEV 1 ). 15 
Quantitative CT evaluation
The HRCT images were obtained from two CT scanners: the Somatom Sensation 16 (Siemens Medical Systems, Forchheim, Germany) and the Lightspeed 16 and plus (GE Healthcare, Milwaukee, WI, USA). CT scans were performed using standard protocols (120-140 kVp; 100-200 mAs; 1 mm slice thickness; 5-10 mm intervals; 0.75 mm collimation; and reconstruction by enhancing kernels of B60f or sharp kernels), at full inspiration and without contrast enhancement.
The texture-based automated quantification system (AQS) was developed as in-house software using the Visual C++ and the Insight Toolkit (Microsoft, Seattle, WA, USA). Each regional pattern consisted of normal, ground-glass opacity, reticular opacity, honeycombing, emphysema and consolidation (Fig. S1 , Supplementary Information). To establish the AQS, the pulmonary parenchyma was quantitatively analysed using a moving functional region-of-interest running through the whole lung field. To estimate the volume of each regional pattern, the area of each class was multiplied by the slice thickness of the HRCT image. The details have been described in previous studies. 16, 17 Emphysema extent was calculated as the proportion of emphysema within the whole lung volume. An emphysema extent of <5% was regarded as insignificant; patients with <5% emphysema were classified as the no/trivial emphysema group.
Statistical analysis
All values are given as the mean AE SD or as a percentage. Fisher's exact test was used to analyse categorical data and the unpaired t-test was used to analyse continuous data. Survival was assessed using Kaplan-Meier survival curves and log-rank test analysis. Cox regression analysis was used to identify significant variables predicting survival. Age, sex and time-adjusted mean differences of FVC at 12 months between the no/trivial emphysema group and emphysema groups were calculated using mixed-effects models. To find the optimal cut-off value at which emphysema impacts the FVC decline rate, we used statistical methods, namely bootstrap, receiver operating characteristic curve-area under the curve (ROC-AUC) and cluster analyses. Bootstrap analysis was applied to t-tests that relied on random sampling with replacement. We used cluster analysis to ensure that patients above the emphysema cut-off value (i.e. a cluster) showed more similarities with each other than with those under the cut-off value. Statistical analyses were performed using SPSS 22.0 (IBM Corporation, Armonk, NY, USA) or R version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria). P-values of <0.05 (two-tailed) were considered significant.
RESULTS
Prevalence of emphysema in IPF
The mean age of the patients was 64.0 years (men: 78.9%, ever-smokers: 73.7%). The median follow-up period was 4.3 years. At least 1% of emphysema was detectable on the HRCT scans of 128 patients (61.2%) and the mean extent was 6.1 AE 5.9%. When emphysema extent was graded in 5% increments, 53 patients (25.4%) had ≥5% emphysema, 23 (11.0%) had ≥10% emphysema and 12 (5.7%) had ≥15% emphysema (Table 1) .
Impacts on FVC decline rate
At a ≥ 5% emphysema cut-off value, men and eversmokers were more frequent, and body mass index was lower in the CPFE group than in the no/trivial emphysema group (Table 1) . The CPFE group also showed more preserved lung volume, higher FEV 1 , lower FEV 1 / FVC and smaller annual FVC decline rates (Fig. 1A) . The adjusted mean difference in FVC change between patients with ≥5% and those with no/trivial emphysema at 12 months was 8.0% (95% CI: 2.2-13.9%, P < 0.001; Fig. 1B ). However, there were no significant differences in DL CO , 6MWT distance (6MWD), 6MWT at lowest oxygen saturation level, CPI and the extent of fibrosis between the two groups. At ≥10% or ≥15% emphysema cut-off values, changes in the baseline value and decline rate of lung function parameters were more remarkable in the CPFE group. Regardless of emphysema cut-off value, the CPFE groups showed similar variations in lung function parameters (higher FVC and TLC, lower FEV 1 /FVC and smaller annual FVC decline rate) than groups under the cut-off values (Table S1 , Supplementary Information). When the extent of emphysema was divided into sections, each group also showed similar results (Table S2 , Supplementary Information).
Impacts on FVC survival prediction
We analysed whether 6MWD, annual FVC decline rate and factors that comprise the Gender, Age, and Physiology (GAP) index 18 could predict survival (Table S3 , Supplementary Information). In patients with no/trivial emphysema, older age, lower FVC and DL CO , shorter 6MWD and larger annual FVC decline rates were associated with a greater mortality risk in univariate analysis. In multivariate analysis, FVC (hazard ratio (HR): 0.981, P = 0.006), 6MWD (HR: 0.997, P = 0.005) and annual FVC decline rate (HR: 0.933, P < 0.001) were independent predictors of mortality (Table 2 ). In patients with ≥5% emphysema, the annual FVC decline rate (HR: 0.906, P < 0.001) and DL CO (HR: 0.955, P < 0.001) were independent predictors of mortality in multivariate analysis. However, in patients with ≥10% emphysema, the annual FVC decline rate was not a significant predictor; DL CO (HR: 0.972, P = 0.040) was the only independent predictor in multivariate analysis (Table 2 ). In the 15% emphysema group, DL CO was also the only predictor of mortality in univariate analysis (HR: 0.942, P = 0.023). The extent of emphysema defining CPFE
Cut-off value for emphysema impacting FVC decline
To investigate the best cut-off value for emphysema impacting annual FVC decline rate, we used several statistical methods (Fig. 2) . The bootstrap method was used to determine alternative cut-off values at which emphysema extent impacts the annual FVC decline rate. In the bootstrap analysis, 11% emphysema was the best cut-off value, as it showed the largest differences in annual FVC decline rate between patients under and over the cut-off value. We also calculated the AUC of the annual FVC decline rate to determine the emphysema cut-off value. When the emphysema cut-off value was 11%, the AUC was calculated to a best value of 0.728 (sensitivity: 0.7, specificity: 0.73). Next, using cluster analysis of the annual FVC decline rate, we calculated the proper emphysema cut-off value. The most favourable cut-off value was approximately 7%. Using this value, the average distances from the centre to the points of each group were minimized, and each group was divided optimally. These statistical analyses suggested that the best cut-off value for emphysema extent impacting the annual FVC decline rate in IPF is between 7% and 11%.
Impacts on survival in IPF
Median survival was 4.8 years (95% CI: 3.2-6.3 years) in IPF patients with ≥5% emphysema, whereas it was 4.2 years (95% CI: 3.5-4.9 years, P = 0.347) in those without emphysema (Table 3 ). The survival rates in patients with CPFE, defined by 10% or 15% cut-off values, were not different from those with no/trivial emphysema (Fig. S2, Supplementary Information ). There were no differences in medication during followup between the emphysema and no/trivial emphysema groups (Table S4 , Supplementary Information). Regardless of the emphysema cut-off value, none of the CPFE groups showed any differences in survival compared with those groups under the cut-off values (Fig. S3 
DISCUSSION
In the present study, we found that emphysema extent of ≥10% can affect both the annual decline rate and the prognostic significance of FVC in IPF. When CPFE was defined at ≥10% emphysema, one-tenth of IPF patients were classified as having CPFE and these patients showed more preserved lung volume, lower annual FVC decline rate and similar prognosis compared with IPF-only patients. In CPFE, DL CO was the best surrogate for predicting subsequent mortality. The emphysema group showed a statistically significant 5.2% less change in FVC over 12 months than the no/trivial emphysema group (95% CI: 0.6-9.4%, P = 0.018). (B) Comparison of adjusted mean differences in FVC between the ≥5% emphysema ( ) and no/trivial emphysema groups ( ) (age, sex and time-adjusted mean differences were calculated using a mixed-effect model. Each line with an error bar represents mean and SE of measurement). Over 12 months, the adjusted mean difference between the two groups was 8.0% and the FVC reduction in the emphysema group was smaller than that in the no/trivial emphysema group (95% CI: 2.2-13.9%, P < 0.001). Emphysema may alter the physiological characteristics of IPF because it mitigates the impact of fibrosis on ventilatory physiology and has cumulative effects on gas exchange. 5 It may also delay lung function decline. 9, 10, 19 Thus, FVC decline, which is the best surrogate marker of disease progression in IPF, may have limited prognostic ability in CPFE. It is for this reason that recent clinical trials of IPF therapy did not include patients with extensive emphysema. 20, 21 However, it remains unclear what emphysema extent impacts the physiological characteristics and prognostic ability of the annual FVC decline rate in IPF. In the present study, even a 5% emphysema extent altered physiological features, including higher FVC and TLC, lower FEV 1 /FVC and slower annual FVC decline in IPF. Emphysema patients also displayed the clinical characteristics of CPFE, such as predominance of male gender and ever-smoking, similar to previous reports. 6, 10, 22 Furthermore, FVC, DL CO , longitudinal lung function changes and CPI have been reported as prognostic factors in IPF. 3, 4, 9 However, emphysema may impact their prognostic value. In a study by Schmidt et al., FVC, DL CO and CPI changes were not predictive, and a 10% FEV 1 decline was the strongest and most consistent predictor of mortality (HR: 3.7, P = 0.046) in IPF patients with moderate-to-severe emphysema. 9 Kim et al. also showed that low DL CO (HR: 0.97, P = 0.017) was independently associated with increased mortality in CPFE patients with honeycombing on CT (HR: 1.95, P = 0.018), but FVC was not. 23 In a study by Kishaba et al., FEV 1 /FVC > 1.2 was a prognostic factor for mortality (HR: 1.93, P = 0.005) in CPFE with finger clubbing (HR: 2.26, P = 0.015). 24 Our study showed that, in IPF-only patients, FVC decline was a significant predictor of mortality, as were FVC and DL CO . However, in patients with ≥10% emphysema, FVC decline lost prognostic significance and DL CO was the only significant prognostic factor. The extent of emphysema defining CPFE In the present study, patients with CPFE, defined using a 10% emphysema cut-off value, showed significant differences in clinical, physiological and prognostic features compared with IPF-only patients. Statistical analysis using bootstrap, ROC-AUC and cluster analysis also supported this result. In a study by Ryerson et al., this emphysema cut-off value showed excellent interrater reliability (κ = 0.74); moreover, CPFE patients defined by this cut-off value showed consistently lower fibrosis on HRCT scans, higher FVC and greater oxygen requirements, irrespective of fibrosis severity. 25 Mejia et al. showed high inter-rater agreement (κ = 0.89) using a cut-off value of ≥10% emphysema, as well as a significantly higher prevalence of PH in CPFE patients than in IPF-only patients. 22 This cut-off value likely corresponds to The Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage-2 disease or worse; 26 patients with such severe emphysema are expected to have symptomatic and physiological consequences. However, in a post hoc analysis of data from the two phase 3 clinical trials of interferon-gamma (IFN-γ)-1b in IPF, Cottin et al. showed that emphysema extent of ≥15% was associated with reduced FVC decline over 48 weeks compared with <15% or no emphysema in patients with IPF (−0.75% vs -3.95%, P = 0.037). 19 This result is not consistent with our findings, probably due to a relatively small number of patients with ≥15% emphysema (12.3% vs 5.7%) and lesser severity (CPI 50.2 vs 37.4) in our cohort.
In the present study, emphysema extent did not affect survival of IPF patients and this finding was consistent with previous studies. 10, 25, 27 Using competing risk analysis, Ryerson et al. showed that patients with CPFE, defined using a 10% emphysema cut-off value, had a similar mortality risk (HR: 1.14, P = 0.69) and disease progression (HR: 1.50, P = 0.57) compared with IPF-only patients, after adjustment for baseline fibrosis. 25 Jacob et al. also suggested that the presence and extent of emphysema had no impact on survival, following correction for baseline disease severity in a large consecutive IPF patient cohort (n = 272). 27 However, the reported impact of CPFE on survival was inconsistent in other studies, 7, 8, 22, 28 because most previous CPFE studies had significant limitations, such as imprecise definitions of CPFE, heterogeneous patient populations and failure to control for confounders. In the present study, CPFE consistently showed no differences in survival compared with IPF, regardless of emphysema cut-off value, after adjustment for age, FVC and DL CO .
The current study had several limitations. First, it was a retrospective study conducted in a single, tertiary referral centre, and it only included patients who could perform multiple PFT and who had no complications during the 1 year after diagnosis. These factors may have led to the longer median survival in our subjects. On the other hand, the demographic features and average lung function were comparable with those in other studies. Second, the number of patients with ≥10% emphysema was relatively small. However, other studies also showed low prevalence of this group (11.6-12.9% of total subjects), 25, 27 and physiological features, including baseline lung function and annual FVC decline rate, were significantly different between patients with and without CPFE in the present study. Third, an AQS was used to evaluate emphysema extent in the current study. Several AQS based on lung attenuation and texture have been shown to objectively evaluate disease extent and to predict clinical outcome in IPF patients. [29] [30] [31] [32] However, several papers have insisted that honeycombing can disturb the evaluation of emphysema extent in CPFE patients. 30, 31 Although there is a risk of misclassification, our AQS showed substantial agreement with visual assessment (by S.M.L.) in the evaluation of emphysema extent (κ = 0.708, P < 0.001), similar to previous studies. 16, 17 In another study, correlations between CT measures of emphysema extent and PFT did not differ significantly between AQS and visual scoring. 30 Finally, we did not evaluate PH, which is one of the most significant prognostic factors in CPFE. This could affect prognostic significance of lung function in our analysis, because DL CO has been shown to correlate with underlying PH in IPF. 33 However, our aim was to estimate the cut-off value at which emphysema impacted the annual decline rate and prognostic significance of FVC and DL CO was considered as covariate in multivariate analysis. Despite these limitations, the current study used objective measurements and various statistical analyses to evaluate the emphysema extent that impacts lung function changes.
In conclusion, our data indicate that emphysema at an extent of ≥10% can be used to define CPFE in IPF patients, and that longitudinal FVC changes are imperfect predictors of subsequent mortality in these patients. Further investigation is needed to monitor disease course and design appropriate clinical trials in these patients.
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